TB500 is not approved by the FDA for human use and is sold only as a research chemical
These thresholds mirror the FDAs own approval criteria for Wegovy and Zepbound
PLAINSBORO, NJ, June 4, 2021 Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss medication with once-weekly dosing
Exclusions included evidence of psychosis or neuropsychiatric illness impairing cognitive abilities
GLP-1 patches , oral drops , and tablet formulations may improve accessibility and tolerability for patients who struggle with injectable medications
Barnes SE, Zera KA, Ivison GT, Buckwalter MS, Engleman EG